A carregar...
Publicação
Plano de exploração para a comercialização de uma molécula inovadora para combater a doença de Parkinson: estudo de caso da molécula NSV-1 da NeuroSoV
| Nome: | Descrição: | Tamanho: | Formato: | |
|---|---|---|---|---|
| Documento em Acesso Embargado até dia 13-10-2028. Tente solicitar cópia ao autor carregando no ficheiro | 1.88 MB | Adobe PDF |
Autores
Orientador(es)
Resumo(s)
A doença de Parkinson (DP) é uma doença neurodegenerativa progressiva que afeta principalmente as funções motoras e cognitivas. Fundamentalmente, é caraterizada pela perda de neurónios dopaminérgicos na substância negra e pela presença de corpos de Lewy nas células nervosas. Os principais sintomas que a DP apresenta são os tremores de repouso, a lentidão dos movimentos, a rigidez muscular e também a perda dos reflexos posturais. Além disso, existem os défices cognitivos e emocionais que incluem a depressão e a demência. As generalidades das terapias da doença estão direcionadas para tratamentos sintomáticos, tais como a medicação com a combinação de L-Dopa/Carbidopa, os agonistas de dopamina, inibidores da MAO-B, anticolinérgicos e amantadina. Em situações específicas são também utilizadas cirurgias com especial destaque para a Estimulação Cerebral Profunda. No entanto, todos estes tratamentos não conseguem ainda alterar a progressão desta doença. Por outro lado, o diagnóstico da doença é por vezes difícil e feito tardiamente o que dificulta uma ação terapeuticamente em fases precoces da doença, prejudicando a ação destes medicamentos. A doença começa a surgir por volta dos 55 anos, mas tem a sua maior incidência a partir dos 65 anos. Atualmente já existe um número muito elevado de pessoas com a doença a nível mundial, mas prevê-se que este número tenha um forte crescimento devido ao aumento do envelhecimento da população mundial. Nesse sentido, estamos a assistir a uma preocupação crescente devido à inexistência de tratamentos que impeça a sua progressão ou a cura, e ao elevado crescimento do número de doentes a nível mundial que se prevê que ocorra continuamente ao longo dos próximos anos. O mercado da DP é muito grande e robusto devido ao interesse e da necessidade para dar resposta ao tratamento dos inúmeros sintomas característicos da doença e da sua evolução lenta ao longo do tempo, causando graves problemas da qualidade de vida dos doentes. Ele é constituído por um grande número de empresas farmacêutica, muitas delas de grande dimensão e de centros de investigação, espalhados por todo mundo. As grandes empresas apresentam infraestruturas e recursos técnicos, científicos e financeiros para o desenvolvimento, produção e distribuição dos medicamentos destinados ao tratamento sintomático da doença. Para dar uma resposta mais eficiente aos problemas atuais sentidos pelos doentes, sistemas de saúde e economia dos países, está-se a assistir a um aumento da investigação e inovação para encontrar novas terapias direcionadas para a cura (terapia modificadora da doença) e deteção precoce da doença. Este interesse está a tornar o mercado mais dinâmico, através do aparecimento de novos centros de investigação e empresas ligadas à investigação e desenvolvimento de novos produtos e tratamentos capazes de retardar a progressão da doença e a sua cura. As grandes empresas que dominam o mercado atual dos tratamentos sintomáticos da doença também estão a efetuar um esforço maior neste tipo de investigação e a realizar consórcios e a compra de patentes ou produtos a outras empresas de menor dimensão, que não têm capacidade para prosseguir com o desenvolvimento dos seus produtos ou descobertas inovadoras. Nesta dinâmica do mercado, encontramos a NeuroSoV que é uma empresa de investigação da área da Biotecnologia que descobriu a molécula NSV-1 com um elevado potencial para impedir a progressão da doença e poder contribuir para a sua cura. Os ensaios pré-clínicos já realizados bem como os testes de segurança e toxicidade, apresentaram resultados positivos, dando à NeuroSoV um ativo de elevado valor comercial. Esta empresa também desenvolveu kits de diagnóstico precoce da doença o que vem reforçar a sua importância no mercado. Para a exploração da molécula NSV-1 da NeuroSoV, encontramos três modelos possíveis, que são a venda da patente ou licença da molécula, o co-desenvolvimento e a comercialização direta. Do resultado da análise das caraterísticas da NeuroSoV e de SWOT, o modelo de exploração da molécula NSV-1 que propomos é o modelo da venda da patente ou licenciamento da molécula a uma grande empresa farmacêutica do mercado (licenciamentoout). Tendo em conta o elevado potencial da molécula, para o desenvolvimento de produtos inovadores para tratamento desta doença, encontramos no mercado um conjunto de grandes empresas farmacêuticas potencialmente interessadas para a compra desta patente, nomeadamente, a Roche, a Novartis, o Grupo Grünenthal, a Pfizer, a AstraZeneca, a Eli Lilly e a Bristol Myers Squibb. A opção pelo modelo da venda da patente (licenciamento-out) proporciona à NeuroSoV minimizar riscos e encargos, ao mesmo tempo que consegue um encaixe financeiro elevado e valoriza a sua molécula mais rapidamente colocando-a no mercado dos medicamentos através de uma grande empresa. Para concretizar o negócio da venda da patente com sucesso, a NeuroSoV tem que ser detentora do registo da patente da molécula nas entidades responsáveis do registo de patentes, informação positiva, sólida e robusta dos resultados dos ensaios pré-clínicos, de segurança e toxicidade, uma grande divulgação do seu produto nos meios científicos (artigos científicos publicados em revistas de referencia internacional) e de mercado (marketing) e uma equipa técnica altamente qualificada para a realização das negociações da venda da patente junto das empresas farmacêuticas.
Parkinson's disease (PD) is a progressive neurodegenerative disease that primarily affects motor and cognitive functions. It is fundamentally characterized by the loss of dopaminergic neurons in the substantia nigra and the presence of Lewy bodies in nerve cells. The main symptoms of PD are resting tremors, slow movement, muscle stiffness, and loss of postural reflexes. Additionally, there are cognitive and emotional deficits, including depression and dementia. Most treatments for the disease focus on symptomatic treatments, such as medication with a combination of L-Dopa/carbidopa, dopamine agonists, MAO-B inhibitors, anticholinergics, and amantadine. In specific situations, surgeries are also used, with a particular emphasis on deep brain stimulation. However, none of these treatments is yet able to halt the progression of the disease. On the other hand, diagnosing the disease is sometimes difficult and delayed, which hinders therapeutic action in its early stages and compromises the effectiveness of these medications. The disease begins to appear around age 55, but its incidence peaks after age 65. Currently, there is already a very high number of people with the disease worldwide, but this number is expected to grow significantly due to the aging of the global population. Therefore, we are witnessing growing concern due to the lack of treatments to prevent its progression or cure, and the high growth in the number of patients worldwide, which is expected to continue over the coming years. The Parkinson's disease market is very large and robust due to the interest and need to address the numerous symptoms characteristic of the disease and its slow progression over time, causing serious problems in the quality of life of patients. It consists of numerous pharmaceutical companies, many of which are large, and research centers spread throughout the world. Large companies have the infrastructure and technical, scientific, and financial resources to develop, produce, and distribute medications for symptomatic treatment of the disease. To more effectively address the current challenges facing patients, healthcare systems, and national economies, research and innovation are increasing to find new therapies aimed at curing (disease-modifying therapies) and early detection of the disease. This interest is making the market more dynamic, with the emergence of new research centers and companies dedicated to developing new products and treatments capable of slowing disease progression and achieving cures. Large companies dominating the current market for symptomatic treatments of the disease are also investing more in this type of research. They are forming consortia and purchasing patents or products from smaller companies that lack the capacity to develop their own products or innovative discoveries further. Within this market dynamic, we find NeuroSoV, a biotechnology research company that discovered the NSV-1 molecule, which has significant potential to prevent disease progression and contribute to its cure. The preclinical trials and safety and toxicity tests already conducted have yielded positive results, giving NeuroSoV a highly valuable commercial asset. This company has also developed early diagnosis kits for the disease, further strengthening its market position. For the development of NeuroSoV's NSV-1 molecule, we identified three possible models: selling the patent or licensing the molecule, co-development, and direct commercialization. Based on the analysis of NeuroSoV's characteristics and SWOT, our proposed model for developing the NSV-1 molecule is to sell the patent or license the molecule to a major pharmaceutical company in the market (out-licensing). Given the molecule's significant potential for developing innovative products to treat this disease, we have identified several large pharmaceutical companies as potentially interested in purchasing this patent, including Roche, Novartis, the Grünenthal Group, Pfizer, AstraZeneca, Eli Lilly, and Bristol Myers Squibb. Opting for the patent sale model (out-licensing) allows NeuroSoV to minimize risks and expenses while simultaneously achieving significant financial returns. This approach also increases the value of its molecule more quickly by placing it on the pharmaceutical market through a large company. To complete the patent sale, NeuroSoV must hold the patent registration of the molecule with the entities responsible for patent registration, positive, solid and robust information on the results of pre-clinical, safety and toxicity tests, extensive publicity for the product in scientific (scientific articles published in internationally renowned journals) and market (marketing) circles, and a highly qualified technical team to carry out negotiations for the sale of the patent with pharmaceutical companies.
Parkinson's disease (PD) is a progressive neurodegenerative disease that primarily affects motor and cognitive functions. It is fundamentally characterized by the loss of dopaminergic neurons in the substantia nigra and the presence of Lewy bodies in nerve cells. The main symptoms of PD are resting tremors, slow movement, muscle stiffness, and loss of postural reflexes. Additionally, there are cognitive and emotional deficits, including depression and dementia. Most treatments for the disease focus on symptomatic treatments, such as medication with a combination of L-Dopa/carbidopa, dopamine agonists, MAO-B inhibitors, anticholinergics, and amantadine. In specific situations, surgeries are also used, with a particular emphasis on deep brain stimulation. However, none of these treatments is yet able to halt the progression of the disease. On the other hand, diagnosing the disease is sometimes difficult and delayed, which hinders therapeutic action in its early stages and compromises the effectiveness of these medications. The disease begins to appear around age 55, but its incidence peaks after age 65. Currently, there is already a very high number of people with the disease worldwide, but this number is expected to grow significantly due to the aging of the global population. Therefore, we are witnessing growing concern due to the lack of treatments to prevent its progression or cure, and the high growth in the number of patients worldwide, which is expected to continue over the coming years. The Parkinson's disease market is very large and robust due to the interest and need to address the numerous symptoms characteristic of the disease and its slow progression over time, causing serious problems in the quality of life of patients. It consists of numerous pharmaceutical companies, many of which are large, and research centers spread throughout the world. Large companies have the infrastructure and technical, scientific, and financial resources to develop, produce, and distribute medications for symptomatic treatment of the disease. To more effectively address the current challenges facing patients, healthcare systems, and national economies, research and innovation are increasing to find new therapies aimed at curing (disease-modifying therapies) and early detection of the disease. This interest is making the market more dynamic, with the emergence of new research centers and companies dedicated to developing new products and treatments capable of slowing disease progression and achieving cures. Large companies dominating the current market for symptomatic treatments of the disease are also investing more in this type of research. They are forming consortia and purchasing patents or products from smaller companies that lack the capacity to develop their own products or innovative discoveries further. Within this market dynamic, we find NeuroSoV, a biotechnology research company that discovered the NSV-1 molecule, which has significant potential to prevent disease progression and contribute to its cure. The preclinical trials and safety and toxicity tests already conducted have yielded positive results, giving NeuroSoV a highly valuable commercial asset. This company has also developed early diagnosis kits for the disease, further strengthening its market position. For the development of NeuroSoV's NSV-1 molecule, we identified three possible models: selling the patent or licensing the molecule, co-development, and direct commercialization. Based on the analysis of NeuroSoV's characteristics and SWOT, our proposed model for developing the NSV-1 molecule is to sell the patent or license the molecule to a major pharmaceutical company in the market (out-licensing). Given the molecule's significant potential for developing innovative products to treat this disease, we have identified several large pharmaceutical companies as potentially interested in purchasing this patent, including Roche, Novartis, the Grünenthal Group, Pfizer, AstraZeneca, Eli Lilly, and Bristol Myers Squibb. Opting for the patent sale model (out-licensing) allows NeuroSoV to minimize risks and expenses while simultaneously achieving significant financial returns. This approach also increases the value of its molecule more quickly by placing it on the pharmaceutical market through a large company. To complete the patent sale, NeuroSoV must hold the patent registration of the molecule with the entities responsible for patent registration, positive, solid and robust information on the results of pre-clinical, safety and toxicity tests, extensive publicity for the product in scientific (scientific articles published in internationally renowned journals) and market (marketing) circles, and a highly qualified technical team to carry out negotiations for the sale of the patent with pharmaceutical companies.
Descrição
Palavras-chave
Doença de Parkinson Neurodegenerativa Tratamento Doença de Parkinson Stress Oxidativo. Molécula NSV-1 NeuroSoV Parkinson's disease Neurodegenerative Parkinson's disease treatment Oxidative stress